Evidence map›Paper›PMID 39801648›Full record

ArticleJACC. CardioOncology2024

Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy.

Maarten J Beekman, Lara Terra, Bernadette A M Heemskerk-Gerritsen, Carlijn M van der Aalst, Jeanine E Roeters van Lennep, Marc van Beurden, Helena C van Doorn, Joanne A de Hullu, Eleonora B L van Dorst, Constantijne H Mom and 26 more

Abstract read
In one paragraph

Article in JACC. CardioOncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Cardiovascular Consequences of Premature Menopause.Current cardiology reports · 2025
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Maarten J BeekmanThe Netherlands Cancer Institute, Amsterdam, the Netherlands.
Lara TerraThe Netherlands Cancer Institute, Amsterdam, the Netherlands.
Bernadette A M Heemskerk-GerritsenErasmus Medical Center, Rotterdam, the Netherlands.
Carlijn M van der AalstErasmus Medical Center, Rotterdam, the Netherlands.
Jeanine E Roeters van LennepErasmus Medical Center, Rotterdam, the Netherlands.
Marc van BeurdenThe Netherlands Cancer Institute, Amsterdam, the Netherlands.
Helena C van DoornErasmus Medical Center, Rotterdam, the Netherlands.
Joanne A de HulluRadboud University Medical Centre, Nijmegen, the Netherlands.
Eleonora B L van DorstUniversity Medical Centre Utrecht, Utrecht, the Netherlands.
Constantijne H MomAmsterdam University Medical Centre, Amsterdam, the Netherlands.
Marian J E MouritsUniversity Medical Centre Groningen, Groningen, the Netherlands.
Brigitte F M SlangenMaastricht University Medical Centre, Maastricht, the Netherlands.
Annemarieke Bartels-RuttenThe Netherlands Cancer Institute, Amsterdam, the Netherlands.
Ricardo P J BuddeErasmus Medical Center, Rotterdam, the Netherlands.
Miranda M SnoerenRadboud University Medical Centre, Nijmegen, the Netherlands.
Tim LeinerMayo Clinic, Rochester, Minnesota, USA.
Pim A de JongUniversity Medical Centre Utrecht, Utrecht, the Netherlands.
Rozemarijn VliegenthartUniversity Medical Centre Groningen, Groningen, the Netherlands.
R Nils PlankenAmsterdam University Medical Centre, Amsterdam, the Netherlands.
Casper MihlMaastricht University Medical Centre, Maastricht, the Netherlands.
Marleen VonderUniversity Medical Centre Groningen, Groningen, the Netherlands.
Matthijs OudkerkInstitute for Diagnostic Accuracy, Groningen, the Netherlands.
Katja N GaarenstroomLeiden University Medical Center, Leiden, the Netherlands.
Jan Willem C GratamaGelre Ziekenhuizen, Apeldoorn, the Netherlands.
Klaartje van EngelenAmsterdam University Medical Centre, Amsterdam, the Netherlands.
Lizet E van der KolkThe Netherlands Cancer Institute, Amsterdam, the Netherlands.
J Margriet ColléeErasmus Medical Center, Rotterdam, the Netherlands.
Marijke R WeversRadboud University Medical Centre, Nijmegen, the Netherlands.
Margreet G E M AusemsUniversity Medical Centre Utrecht, Utrecht, the Netherlands.
Lieke P V BergerUniversity Medical Centre Groningen, Groningen, the Netherlands.
Encarna B Gomez GarciaMaastricht University Medical Centre, Maastricht, the Netherlands.
Christi J van AsperenLeiden University Medical Center, Leiden, the Netherlands.
Maartje J HooningErasmus Medical Center, Rotterdam, the Netherlands.
Harry J de KoningErasmus Medical Center, Rotterdam, the Netherlands.
Angela H E M MaasRadboud University Medical Centre, Nijmegen, the Netherlands.
Flora E van LeeuwenThe Netherlands Cancer Institute, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Premenopausal risk-reducing salpingo-oophorectomy (RRSO) in women at high familial risk of ovarian cancer leads to immediate menopause. Although early natural menopause is associated with increased cardiovascular disease risk, evidence on long-term cardiovascular disease risk after early surgical menopause is scarce. Objectives: We sought to determine the long-term influence of the timing of RRSO on the development of coronary artery calcium (CAC), an established marker for cardiovascular disease risk. Methods: We conducted a cross-sectional study (N = 733) nested in a nationwide cohort of women at high familial risk of ovarian cancer. In women aged 60-70 years (n = 328), we compared CAC scores between women with a premenopausal RRSO (age ≤45 years) and women with a postmenopausal RRSO (age ≥54 years), using multivariable Poisson analyses. Within the premenopausal RRSO group (n = 498), we also examined the effect of age at RRSO. In addition, we compared the premenopausal RRSO group with an external reference cohort (n = 5,226). Results: Multivariable analyses showed that the prevalence rates of any CAC (CAC >0), at least moderate CAC (CAC >100), and severe CAC (CAC >400) were comparable between the premenopausal and postmenopausal RRSO groups (relative risk [RR]: 0.93; 95% CI: 0.75-1.15 for any CAC; RR: 0.71; 95% CI: 0.43-1.17 for at least moderate CAC; RR: 0.81; 95% CI: 0.30-2.13 for severe CAC). There was no difference in CAC between the premenopausal RRSO group and a similar aged reference cohort. Timing of premenopausal RRSO (early premenopausal RRSO [<41 years] vs late premenopausal RRSO [41-45 years]) did not affect the outcomes. Conclusions: Our results do not show a long-term adverse effect of surgical menopause on the development of CAC.

Indexed as

BRCACACcardiovascular diseaseovarian cancerRRSOsurgical menopause

Identifiers

PMID39801648
PMCPMC11711998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.